Thomas Edwards, MD
Allergy & Immunology · Worcester, MANPI 1740215771
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,369 of the $23,107 with a category attached, or 79.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $7,510 and has fallen 55.7% since, to $3,327 in 2025.
Across 847 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Blueprint Medicines Corporation$5K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Pfizer$848
- Sanofi$782
- plus $7K from 26 others
What the payments were for
- Speaking & faculty fees$2,60511%
- Travel & lodging$1,9518%
- Food & beverage$18,36979%
- Education$1811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 207 | $5,482 |
| Blueprint Medicines Corporation | 23 | $5,367 |
| GSK | 163 | $2,499 |
| Regeneron Healthcare Solutions, Inc. | 72 | $1,444 |
| Pfizer | 44 | $848 |
| Sanofi | 33 | $782 |
| Novartis | 44 | $779 |
| CSL Behring | 29 | $776 |
| Genentech USA, Inc. | 32 | $755 |
| Amgen | 36 | $645 |
| Pharming Healthcare, Inc. | 13 | $484 |
| Grifols USA, LLC | 22 | $440 |
| Boehringer Ingelheim | 17 | $311 |
| Optinose US, Inc. | 16 | $309 |
| Teva Pharmaceuticals USA, Inc. | 28 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $270 |
| Kaleo, Inc. | 10 | $247 |
| Biocryst US Sales Co., LLC | 6 | $244 |
| AbbVie | 9 | $232 |
| Aimmune Therapeutics, Inc. | 7 | $147 |
| Lilly USA, LLC | 5 | $119 |
| Dermavant Sciences, Inc. | 1 | $105 |
| Sanofi-aventis U.S. LLC | 2 | $97 |
| Greer Laboratories, Inc. | 1 | $96 |
| Octapharma USA, Inc. | 4 | $88 |
| ADMA Biomanufacturing LLC | 1 | $51 |
| GC Biopharma USA, Inc. | 2 | $49 |
| Galderma Laboratories, L.p. | 3 | $49 |
| LEO Pharma Inc. | 2 | $42 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Merck | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,107 in reported general payments places this provider in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 27 | $145,047 |
| XolairOmalizumab | 34 | $144,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $105,521 |
| TezspireTezepelumab-Ekko | 11 | $45,982 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $38,902 |
| OpzeluraRuxolitinib Phosphate | 12 | $23,449 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $20,857 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $16,355 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $13,504 |
| Serevent DiskusSalmeterol Xinafoate | 17 | $12,506 |
| Pulmicort FlexhalerBudesonide | 32 | $9,957 |
| Arnuity ElliptaFluticasone Furoate | 24 | $8,368 |
| Epinephrine | 29 | $6,659 |
| AirsupraAlbuterol Sulfate/Budesonide | 11 | $5,124 |
| DuleraMometasone/Formoterol | 15 | $4,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,499 | $169,145222 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Pulmicort Flexhaler, Airsupra | $5,482 | $81,91976 claims |
| MerckDulera | $17 | $4,88115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Worcester
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
- Ami MehraChelmsford$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.